Publications (6)8.25 Total impact
-
Article: With so much Attention Paid to Adenosine Diphosphate Receptor Blockers, Is There Still a Role for Aspirin Resistance?
Revista Espa de Cardiologia 11/2012; · 2.53 Impact Factor -
Article: Olmesartan for the Prevention or Delay of Diabetic Nephropathy: Some Considerations. Response.
Revista Espa de Cardiologia 05/2012; 65(7):679-680. · 2.53 Impact Factor -
Article: Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
Revista Espanola de Cardiologia 08/2011; 65(4):378-80. -
Article: [Thrombectomy in the acute myocardial infarction: A success in the fight against incomplete myocardial perfusion].
[show abstract] [hide abstract]
ABSTRACT: Currently, the preferred treatment of persistent ST-segment elevation acute myocardial infarction is primary angioplasty. After successful primary angioplasty, up to 30% of patients develop left ventricular dilation and heart failure, as a result of incomplete microvascular reperfusion. The pathophysiology of the microvascular dysfunction in the setting of primary angioplasty is complex and not completely known. Distal embolization of necrotic and thrombotic material acts as a mayor factor. No treatment has so far demonstrated proven efficacy in this scenario. However, several prophylactic measures have been identified. Among them, the rheolytic trombectomy offers interesting benefits both in surrogate and clinical outcome variables.Medicina Clínica 06/2009; 134(5):211-7. · 1.38 Impact Factor -
Article: [Influence of comorbidity on admission management and pharmacological treatment prescribed at discharge in acute myocardial infarction].
[show abstract] [hide abstract]
ABSTRACT: The management of cardiac ischemic patients differs depending on their comorbidity. The Charlson Index (ChI) and its adaptations are well established and widely used tools to quantify a patient comorbidity. The aim of this study is to evaluate the influence of comorbidity quantified by the ChI in the treatment administered at admission and in the pharmacological treatment prescribed at discharge in the setting of an acute myocardial infarction with and without ST segment elevation. We studied a total of 955 patients consecutively admitted in our hospital with the diagnosis of acute myocardial infarction. Comorbidity was obtained at the first day of admission applying the ChI. According to this value patients were classified from minor to major in 2 subgroups (ChI <or= 2, ChI >or= 2) and differences in the admission and discharge treatments between both groups were analyzed. Patients admitted with acute myocardial infarction without ST segment elevation and ChI > 2 received less frequently betablockers at discharge, but there were no significant differences in the use of ACE inhibitors, calcium channel blockers or statins. In addition they were submitted less frequently to revascularization procedures or treadmills, and no differences were found in the use of echocardiograms. Patients with ST segment elevation and ChI > 2 were less frequently treated with betablockers or statins at discharge, and were submitted to less treadmills or echocardiograms; furthermore, in these patients, there were no significant differences in the use of ACE inhibitors, calcium channel blockers, thrombolytics or revascularization procedures. Comorbidity quantified on admission by the ChI is an independent factor that modifies in-hospital and ambulatory management of patients with acute myocardial infarction. There is a lower use of invasive techniques as well as a lower prescription of betablockers at discharge in patients with greater comorbidity.Medicina Clínica 04/2005; 124(12):447-50. · 1.38 Impact Factor -
Article: [Prognostic impact of anemia in acute heart failure].
[show abstract] [hide abstract]
ABSTRACT: Studies performed on selected patients in other countries have shown that anemia is frequently associated with heart failure and results in a worse prognosis. We sought to determine the prognosis significance of hemoglobin/anemia in patients with acute heart failure which required management with hospital admission. We analysed 412 patients diagnosed with acute heart failure as outlined in the criteria of the European Society of Cardiology (ESC). We measured hemoglobin within the first 24 hours and obtained demographic, clinical and biochemical variables. Anemia was defined in accordance with OMS criteria. The main variable was all-cause mortality. The association between all-cause mortality and hemoglobin/anemia was determined using the multiple regression Cox model. During follow-up (median six months) we observed 101 all-cause mortality events. In the multivariate analysis, hemoglobin was an independent predictive variable adjusted by covariates (HR 1.15, IC 95% [1.04-1.25], p = 0.014). Anemia (hemoglobin < 13 g/dL) was also found to be an independent predictive variable adjusted by covariates (HR 2.06, IC al 95% [1.28-3.33], p = 0.003). Hemoglobin and anemia (hemoglobin < 13 g/dL) are consistently associated with short-term, poorer survival in patients with acute heart failure.Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 58(4):279-84. · 0.42 Impact Factor
